Literature DB >> 25656230

Chronic clenbuterol treatment compromises force production without directly altering skeletal muscle contractile machinery.

G Py1, C Ramonatxo, P Sirvent, A M J Sanchez, A G Philippe, A Douillard, O Galbès, C Lionne, A Bonnieu, A Chopard, O Cazorla, A Lacampagne, R B Candau.   

Abstract

Clenbuterol is a β2 -adrenergic receptor agonist known to induce skeletal muscle hypertrophy and a slow-to-fast phenotypic shift. The aim of the present study was to test the effects of chronic clenbuterol treatment on contractile efficiency and explore the underlying mechanisms, i.e. the muscle contractile machinery and calcium-handling ability. Forty-three 6-week-old male Wistar rats were randomly allocated to one of six groups that were treated with either subcutaneous equimolar doses of clenbuterol (4 mg kg(-1) day(-1) ) or saline solution for 9, 14 or 21 days. In addition to the muscle hypertrophy, although an 89% increase in absolute maximal tetanic force (Po ) was noted, specific maximal tetanic force (sPo) was unchanged or even depressed in the slow twitch muscle of the clenbuterol-treated rats (P < 0.05). The fit of muscle contraction and relaxation force kinetics indicated that clenbuterol treatment significantly reduced the rate constant of force development and the slow and fast rate constants of relaxation in extensor digitorum longus muscle (P < 0.05), and only the fast rate constant of relaxation in soleus muscle (P < 0.05). Myofibrillar ATPase activity increased in both relaxed and activated conditions in soleus (P < 0.001), suggesting that the depressed specific tension was not due to the myosin head alteration itself. Moreover, action potential-elicited Ca(2+) transients in flexor digitorum brevis fibres (fast twitch fibres) from clenbuterol-treated animals demonstrated decreased amplitude after 14 days (-19%, P < 0.01) and 21 days (-25%, P < 0.01). In conclusion, we showed that chronic clenbuterol treatment reduces contractile efficiency, with altered contraction and relaxation kinetics, but without directly altering the contractile machinery. Lower Ca(2+) release during contraction could partially explain these deleterious effects.
© 2015 The Authors. The Journal of Physiology © 2015 The Physiological Society.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25656230      PMCID: PMC4405760          DOI: 10.1113/jphysiol.2014.287060

Source DB:  PubMed          Journal:  J Physiol        ISSN: 0022-3751            Impact factor:   5.182


  44 in total

1.  Effects of terbutaline on force and intracellular calcium in slow-twitch skeletal muscle fibres of the rat.

Authors:  T N Ha; G S Posterino; M W Fryer
Journal:  Br J Pharmacol       Date:  1999-04       Impact factor: 8.739

2.  At physiological temperatures the ATPase rates of shortening soleus and psoas myofibrils are similar.

Authors:  R Candau; B Iorga; F Travers; T Barman; C Lionne
Journal:  Biophys J       Date:  2003-11       Impact factor: 4.033

3.  Acute inhibitory effects of clenbuterol on force, Ca²⁺ transients and action potentials in rat soleus may not involve the β₂-adrenoceptor pathway.

Authors:  Stewart I Head; Tuyen N V Ha
Journal:  Clin Exp Pharmacol Physiol       Date:  2011-09       Impact factor: 2.557

Review 4.  Overview of the effects of beta-adrenergic receptor agonists on animal growth including mechanisms of action.

Authors:  H J Mersmann
Journal:  J Anim Sci       Date:  1998-01       Impact factor: 3.159

5.  High-dose inhaled terbutaline increases muscle strength and enhances maximal sprint performance in trained men.

Authors:  Morten Hostrup; Anders Kalsen; Jens Bangsbo; Peter Hemmersbach; Sebastian Karlsson; Vibeke Backer
Journal:  Eur J Appl Physiol       Date:  2014-08-12       Impact factor: 3.078

6.  Effects of repetitive tetanic stimulation at long intervals on excitation-contraction coupling in frog skeletal muscle.

Authors:  J D Bruton; J Lännergren; H Westerblad
Journal:  J Physiol       Date:  1996-08-15       Impact factor: 5.182

7.  Effect of acute and short-term oral salbutamol treatments on maximal power output in non-asthmatic athletes.

Authors:  Anthony M J Sanchez; Katia Collomp; Juliette Carra; Fabio Borrani; Olivier Coste; Christian Préfaut; Robin Candau
Journal:  Eur J Appl Physiol       Date:  2012-01-10       Impact factor: 3.078

8.  Time course in calpain activity and autolysis in slow and fast skeletal muscle during clenbuterol treatment.

Authors:  Aymeric Douillard; Olivier Galbes; Bernadette Rossano; Barbara Vernus; Anne Bonnieu; Robin Candau; Guillaume Py
Journal:  Can J Physiol Pharmacol       Date:  2011-02       Impact factor: 2.273

9.  Effects of clenbuterol on contractile and biochemical properties of skeletal muscle.

Authors:  S L Dodd; S K Powers; I S Vrabas; D Criswell; S Stetson; R Hussain
Journal:  Med Sci Sports Exerc       Date:  1996-06       Impact factor: 5.411

10.  Effects of chronic administration of clenbuterol on contractile properties and calcium homeostasis in rat extensor digitorum longus muscle.

Authors:  Pascal Sirvent; Aymerick Douillard; Olivier Galbes; Christelle Ramonatxo; Guillaume Py; Robin Candau; Alain Lacampagne
Journal:  PLoS One       Date:  2014-06-27       Impact factor: 3.240

View more
  2 in total

1.  Early structural and functional signature of 3-day human skeletal muscle disuse using the dry immersion model.

Authors:  Rémi Demangel; Loïc Treffel; Guillaume Py; Thomas Brioche; Allan F Pagano; Marie-Pierre Bareille; Arnaud Beck; Laurence Pessemesse; Robin Candau; Claude Gharib; Angèle Chopard; Catherine Millet
Journal:  J Physiol       Date:  2017-04-23       Impact factor: 5.182

2.  Role of phosphodiesterase 4 expression in the Epac1 signaling-dependent skeletal muscle hypertrophic action of clenbuterol.

Authors:  Yoshiki Ohnuki; Daisuke Umeki; Yasumasa Mototani; Kouichi Shiozawa; Megumi Nariyama; Aiko Ito; Naoya Kawamura; Yuka Yagisawa; Huiling Jin; Wenqian Cai; Kenji Suita; Yasutake Saeki; Takayuki Fujita; Yoshihiro Ishikawa; Satoshi Okumura
Journal:  Physiol Rep       Date:  2016-05
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.